Clinical Trial Update: Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tacrolimus for hereditary hemorrhagic telangiectasia-related epistaxis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Unity Health Toronto | Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed | Phase 2 | Status: COMPLETED